论文部分内容阅读
目的:评价以吉西他滨为主的联合化疗方案治疗晚期乳腺癌的疗效与不良反应。方法:对经病理确诊的Ⅳ期乳腺癌患者32例,采用以吉西他滨为主的联合化疗方案进行化疗。吉西他滨的剂量为800～1000mg/m2,d1、d8、d15,其它化疗药物采用常规剂量。每4周为1周期,2周期后评价疗效。结果:全组患者均可评价疗效,其中完全缓解(CR)3例(9.4%),部分缓解(PR)13例(40.6%),稳定(SD)10例(31.3%),进展(PD)6例(18.8%),总有效率(ORR)为50.0%,TTP6.8个月,MOS14.6个月;Ⅲ-Ⅳ度毒副反应分别为血小板减少19.0%,白细胞减少14.0%,发热11.0%,恶心或呕吐9.0%。结论:以吉西他滨为主的联合化疗方案治疗晚期乳腺癌的近期疗效较好,生存时间有所延长,患者耐受性较好。
Objective: To evaluate the efficacy and side effects of gemcitabine-based combination chemotherapy in the treatment of advanced breast cancer. Methods: Thirty-two patients with pathologically confirmed stage IV breast cancer were treated with chemotherapy combined with gemcitabine-based chemotherapy. Gemcitabine dose of 800 ~ 1000mg / m2, d1, d8, d15, other chemotherapy drugs using conventional dose. Every 4 weeks for 1 cycle, 2 cycles after the evaluation of efficacy. Results: All the patients were evaluated for efficacy, including 3 cases of complete remission (CR), 13 cases of partial remission (PR), 10 cases of stable (SD), 31 cases of progressive (PD) 6 cases (18.8%), the total effective rate (ORR) was 50.0%, TTP 6.8 months, MOS 14.6 months; Ⅲ-Ⅳ degrees of toxicity were thrombocytopenia 19.0%, leukopenia 14.0%, fever 11.0 %, Nausea or vomiting 9.0%. Conclusion: The combination of gemcitabine-based chemotherapy in the treatment of advanced breast cancer has a good short-term effect, prolonged survival, patients with better tolerance.